Delving into the Latest Updates on PM-1009 with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

PM 1009, PM1009

Target

CD112R x TIGIT

Mechanism

CD112R antagonists(Transmembrane protein PVRIG antagonists), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases

Active Indication

Metastatic hepatocellular carcinomaHepatocellular CarcinomaAdvanced cancer+ [2]

Inactive Indication-

Originator Organization

Pumis Biotechnology (Zhuhai) Co., Ltd.Startup

Active Organization

Pumis Biotechnology (Zhuhai) Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1009.
PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.

Start Date21 Nov 2022

Sponsor / Collaborator

Pumis Biotechnology (Zhuhai) Co., Ltd.Startup

CTR20222519 / RecruitingPhase 1

评价PM1009注射液在晚期肿瘤患者中的耐受性、安全性、药代动力学特征和初步疗效的I 期临床试验

[Translation] Phase I clinical trial to evaluate the tolerability, safety, pharmacokinetic characteristics and preliminary efficacy of PM1009 injection in patients with advanced tumors

主要目的：评价PM1009在晚期肿瘤受试者治疗中的耐受性和安全性。

[Translation]

Primary objective: To evaluate the tolerability and safety of PM1009 in the treatment of subjects with advanced tumors.

Start Date17 Nov 2022

Sponsor / Collaborator

Pumis Biotechnology (Zhuhai) Co., Ltd.Startup

100 Clinical Results associated with PM-1009

Login to view more data

100 Translational Medicine associated with PM-1009

Login to view more data

100 Patents (Medical) associated with PM-1009

Login to view more data

100 Deals associated with PM-1009

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic hepatocellular carcinoma	Phase 2	-	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	01 Oct 2024
Hepatocellular Carcinoma	Phase 2	CN	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	30 Aug 2024
Advanced cancer	Phase 1	CN	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	17 Nov 2022
Locally Advanced Hepatocellular Carcinoma	IND Approval	CN	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	10 Jul 2024
Lung Cancer	IND Approval	CN	Pumis Biotechnology (Zhuhai) Co., Ltd.Startup	20 Sep 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05607563 (PM1009, ASCO2024)	Phase 1	Advanced Malignant Solid Neoplasm	12	PM1009 120 mg	cvnoifycif(nafbheitnz) = zyyvjhifpf blolavaxvn (fcobytdwvm, 9.92 - 65.11) View more	Positive	24 May 2024
				PM1009 300 mg	cvnoifycif(nafbheitnz) = cfdyallrzt blolavaxvn (fcobytdwvm, 9.92 - 65.11) View more